Tech Company Financing Transactions
Arthrosi Therapeutics Funding Round
On 10/8/2025, Arthrosi Therapeutics raised $153 million in Series E funding from CR Ventures, HighLight Capital and HM Capital.
Transaction Overview
Company Name
Announced On
10/8/2025
Transaction Type
Venture Equity
Amount
$153,000,000
Round
Series E
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9855 Towne Centre Dr 200
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Arthrosi Therapeutics, Inc. was founded in San Diego, CA, in 2018, by a world-class team of gout experts who spearheaded the clinical development of the first generation of urate inhibitor treatment for gout at Ardea Biosciences resulting in a $1.26 Billion acquisition by AstraZeneca. With its vast therapeutic and treatment knowledge, Arthrosi has efficiently completed multiple robust phase 1 and 2 clinical studies in a mere two years and accumulated a comprehensive and robust intellectual property portfolio.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Litain Yeh
Chief Medical Officer
Robert Keenan
Chief Operating Officer
Shunqi Yan
Browse more venture capital transactions:
Prev: 10/8/2025: Reo.Dev venture capital transaction
Next: 10/8/2025: Asante Gold venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs